Limit up with buying interest. After the close of trading on the 20th, it was announced that the company had signed an exclusive licensing agreement with Asahi Kasei Pharma for the company's therapeutic antibody 'Humanized anti-CX3CR1 antibody', considered positive news. PFKR granted Asahi Kasei Pharma exclusive worldwide development, manufacturing, and sales rights with sublicensing rights. In addition to receiving a one-time contract fee of ¥0.2 billion, the company will receive milestone payments of up to approximately ¥24.8 billion based on future developments and sales progress. Furthermore, upon product launch, it will receive royalties based on product revenue.
カイオム---ストップ高買い気配、旭化成ファーマとの間で独占的ライセンス契約を締結
Kaiom - High buying interest at the stop price, a monopoly licensing agreement has been concluded with Asahi Kasei Pharma.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha